BETABiohacksAI is a research tool for informational purposes only. All outputs are computational hypothesis candidates — not confirmed mechanisms, not medical advice, and not a substitute for professional medical judgment. Independent experimental validation is always required.
BiohacksAI is an evolving scientific literature platform. New compounds and evidence are indexed continuously.
B

Rifamycin Sv

A group of ANTI-BACTERIAL AGENTS characterized by a chromophoric naphthohydroquinone group spanned by an aliphatic bridge not previously found in other known ANTI-BACTERIAL AGENTS. They have been isolated from fermentation broths of Streptomyces mediterranei.

300+ PubMed studies analyzed · 11 RCTs · Evidence Score: 45.3

Research Domains

Rifamycin Sv has been studied across 15 research domains including 🫁 Liver & Detox, 🫁 Respiratory, 🦴 Bone & Joint, 🫘 Kidney, ✨ Skin & Hair. The primary research focus is 🫁 Liver & Detox with 13% of studies addressing this area.

Similar Compounds by Shared Targets

The following compounds share molecular targets with Rifamycin Sv, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.

Silymarin
3 shared targets
Pravastatin
3 shared targets
Olmesartan
4 shared targets
beta
3 shared targets
Taurocholic
3 shared targets
Losartan
6 shared targets
Taurochenodeoxycholic
2 shared targets
Dehydroepiandrosterone
2 shared targets
Clindamycin
2 shared targets
Ritonavir
7 shared targets
Loading evidence profile...

This evidence profile for Rifamycin Sv is generated deterministically from 300 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.

Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.